Key result
The Hospital Readmission Reduction Program was associated with a 2.6% reduction in 30-day hospital readmission rates, a 7.9% decrease in length of stay, and a 2.1% increase in hospital satisfaction ratings compared to non-HRRP hospitals.
Why the study?
The impact of the Hospital Readmission Reduction Program on a comprehensive set of Triple Aim goals has not been studied.
Does the Hospital Readmission Reduction Program (HRRP) improve 30-day readmission rates, length of stay, and patient satisfaction in patients with COPD and congestive heart failure?
Observational (n=27,397)
Yes
Does the Hospital Readmission Reduction Program (HRRP) improve 30-day readmission rates, length of stay, and patient satisfaction in patients with COPD and congestive heart failure?
The HRRP successfully reduced 30-day readmissions and length of stay while marginally improving patient satisfaction, indicating hospitals did not trade off quality or patient experience to avoid penalties.
Answers are grounded in this paper and cite their sources.
HRRP-associated gains in readmissions, LOS, and satisfaction seen in cohort data; leaves open whether policy causes these outcomes in COPD and HF.
OBJECTIVES: Despite substantial attention on hospital readmission rates, the impact of the Hospital Readmission Reduction Program (HRRP) on a comprehensive set of Triple Aim goals has not been studied: improve hospital quality, reduce cost, and improve patient experience. METHODS: We analyze inpatient claims data from 2006 to 2015 from the Dallas Fort Worth Hospital Council Foundation with a panel of 27,397 patients with chronic obstructive pulmonary disease and congestive heart failure. We deploy a quasi-natural experiment using a difference-in-difference specification to estimate the effect of HRRP effect on readmission rates, length of stay (LOS), and hospital satisfaction. RESULTS: We find that the likelihood of 30-day readmissions declined by 2.6%, average LOS decreased by 7.9%, and overall hospital rating increased by 2.1% among hospitals that fell under the scope of the HRRP, compared to non-HRRP hospitals. Our results provide evidence of a spillover effect of the HRRP in terms of its impact not only on Medicare patients, but across all insurance types, and other performance measures such as cost and patient experience. CONCLUSION: Our findings indicate that HRRP hospitals do not trade-off reductions in readmission rates with lower quality across other patient health outcomes. Rather, we find evidence that the HRRP has affected all 3 dimensions of the Triple Aim with respect to patient and hospital outcomes.
No takes yet. Share an insight, caveat, or question.
Ayabakan et al. (2021) conducted an observational in Chronic obstructive pulmonary disease and congestive heart failure (n=27,397). Hospital Readmission Reduction Program (HRRP) vs. Non-HRRP hospitals was evaluated on 30-day hospital readmission rate (18.1% decrease in odds, p=<0.01). The Hospital Readmission Reduction Program was associated with a 2.6% reduction in 30-day hospital readmission rates, a 7.9% decrease in length of stay, and a 2.1% increase in hospital satisfaction ratings compared to non-HRRP hospitals.
Synapse has enriched 10 related papers. Consider them for comparative context: